How Does the COVID-19 Antiviral Medications Workflow Compare to the Traditional Antiviral Production Pipeline
The discussion focuses on comparing the traditional antiviral production pipeline to the workflow used for producing COVID-19 antiviral medications. Dr. Kishor Wasan shares insights into how COVID-19 vaccine research differs from past practices in antiviral and antibiotic production. The conversation aims to highlight the differences and similarities in treatment development for COVID-19 versus other viruses.
This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.
Key takeaways
Researchers are learning more about COVID-19 to effectively combat it.
Differences are noted in the COVID-19 vaccine production versus traditional antiviral pipelines.
Get featured
Want to get featured in MarketScale Sciences?
Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.
As the COVID-19 pandemic continues to progress researchers and scientists are starting to learn more about the virus in order to effectively combat it. One of those lessons is how the COVID-19 virus compares to other viruses when it comes to developing treatments. Justin Honore talked to Dr. Kishor Wasan, PH.D.,FAAPS, FCAHS, FCSPS, Chief Medical & Scientific Officer at Skymount Medical and a Distinguished University Scholar Adjunct Professor at the University of British Columbia about how COVID-19 vaccine research and production compare to the traditional antiviral and antibiotic production pipeline.
Your experts belong here
Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.
Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.
About the author
